Novartis AG (NVS) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Novartis’s revenue went from $48.5B in fiscal 2016 to $54.5B in fiscal 2025, growth of about 1.3% a year.
Net income in fiscal 2025 was $14.0B, a net margin of 25.6%; the best year in this period was 2021 with $24.0B.
Over the twelve months to September 30, 2026, revenue was $57.4B and net income $10.0B.
Free cash flow was $17.6B in fiscal 2025 and positive in 10 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57.4B | $54.5B | $50.3B | $45.4B | $42.2B | $42.8B | $48.7B | $47.5B | $44.8B | $42.4B | $48.5B |
| Gross profit | — | $43.0B | $38.9B | $34.2B | $31.9B | $32.2B | $34.8B | $34.3B | $31.6B | $29.8B | $31.9B |
| Operating income | — | $17.6B | $14.5B | $9.8B | $7.9B | $10.1B | $10.2B | $9.1B | $8.4B | $8.7B | $8.3B |
| Net income | $10.0B | $14.0B | $11.9B | $14.8B | $7.0B | $24.0B | $8.1B | $11.7B | $12.6B | $7.7B | $6.7B |
| EPS (diluted) | $5.23 | $7.33 | $6.26 | $7.78 | $3.64 | $12.59 | $4.23 | $6.15 | $6.61 | $4.04 | $3.52 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +8.4% | +10.7% | +7.7% | −1.3% | −12.1% | +2.4% | +5.9% | +5.8% | −12.7% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.3B | $19.1B | $17.6B | $14.5B | $14.2B | $15.1B | $13.7B | $13.6B | $14.3B | $12.6B | $11.5B |
| Capital spending | -$3.3B | -$1.5B | -$1.4B | -$1.1B | -$916M | -$1.1B | -$1.3B | -$1.4B | -$1.3B | -$1.3B | -$1.9B |
| Free cash flow | $14.0B | $17.6B | $16.3B | $13.4B | $13.3B | $14.0B | $12.4B | $12.2B | $13.0B | $11.3B | $9.6B |
| Dividends paid | $9.1B | $7.8B | $7.6B | $7.3B | $7.5B | $7.4B | $7.0B | $6.6B | $7.0B | $6.5B | $6.5B |
| Buybacks | — | $9.2B | $8.3B | $8.7B | $10.7B | $3.1B | $2.8B | $5.5B | $2.0B | $5.5B | $1.1B |
| Stock-based pay | — | $1.1B | $1.0B | $865M | $791M | $700M | $738M | $758M | $673M | $612M | $671M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $11.4B | $11.5B | $13.4B | $7.5B | $12.4B | $9.7B | $11.1B | $13.3B | $8.9B | $7.0B |
| Debt | — | $28.7B | $24.7B | $20.6B | $22.5B | $25.5B | $28.5B | $22.4B | $25.7B | $23.6B | — |
| Equity | — | $46.1B | $44.0B | $46.7B | $59.3B | $67.7B | $56.6B | $55.5B | $78.6B | $74.2B | $74.9B |
| Total assets | — | $110.9B | $102.2B | $99.9B | $117.5B | $131.8B | $127.8B | $118.4B | $145.6B | $133.1B | — |
| Shares (diluted) | 1.92B | 1.91B | 1.91B | 1.91B | 1.91B | 1.91B | 1.91B | 1.91B | 1.91B | 1.91B | 1.91B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 78.8% | 77.3% | 75.2% | 75.5% | 75.4% | 71.5% | 72.1% | 70.5% | 70.2% | 65.8% |
| Operating margin | — | 32.4% | 28.9% | 21.5% | 18.8% | 23.5% | 20.9% | 19.1% | 18.7% | 20.5% | 17.0% |
| Net margin | 17.5% | 25.6% | 23.7% | 32.7% | 16.5% | 56.1% | 16.6% | 24.7% | 28.1% | 18.2% | 13.8% |
| FCF margin | 24.4% | 32.3% | 32.3% | 29.5% | 31.6% | 32.7% | 25.4% | 25.8% | 29.0% | 26.7% | 19.8% |
| ROIC | — | 20.1% | 18.5% | 13.6% | 8.2% | 10.1% | 9.7% | 9.3% | 7.3% | 7.3% | 9.5% |
| ROE | — | 30.3% | 27.1% | 31.8% | 11.7% | 35.5% | 14.3% | 21.1% | 16.0% | 10.4% | 9.0% |
Frequently asked questions
What is Novartis’s annual revenue?
$54.5B in fiscal 2025 and $57.4B over the twelve months to September 30, 2026.
How much profit does Novartis make?
Net income was $14.0B in fiscal 2025 (net margin 25.6%).
Is Novartis’s revenue growing?
Yes: revenue rose 8.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.